Integral Health Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Integral Health Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-412,000	Closed	-$2.05M	–	67
2023 Q2	$2.05M	Buy	412,000 +7,000	+2%	+$37.9K	0.25%	70
2023 Q1	$2M	Buy	+405,000	New	+$2.6M	0.4%	62
2021 Q2	–	Sell	-60,000	Closed	-$2.12M	–	72
2021 Q1	$2.12M	Buy	+60,000	New	+$2.02M	0.61%	52

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Integral Health Asset Management's ALLO Position: Q3 2023 in Review

Integral Health Asset Management sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 412,000 shares — an estimated $2.05M sold.

Integral Health Asset Management first reported a position in ALLO in Q1 2021 and held it in 3 quarters. The position peaked at $2.12M in Q1 2021. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

Integral Health Asset Management reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
Integral Health Asset Management sold 412,000 Allogene Therapeutics shares in Q3 2023, an estimated $2.05M.
Integral Health Asset Management first reported a position in Allogene Therapeutics in Q1 2021 and held it in 3 quarters.
Integral Health Asset Management's Allogene Therapeutics position peaked at $2.12M in Q1 2021.
154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Integral Health Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.